Sarlósejtes vérszegénység: vizsgálatok itt: Omán
5 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Where
- Muscat
- Életkor
- 10 év to 65 év
- People
- 192 worldwide
- Run by
- Sanofi
See details and how to joinNCT06975865 - 3. fázisTaking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Muscat
- Életkor
- 2 év and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - 3. fázisTaking peopleA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Where
- Muscat
- Életkor
- 12 év and over
- People
- 510 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00 - 2. fázisTaking peopleA Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
- Where
- Muscat
- Életkor
- 12 év to 16 év
- People
- 27 worldwide
- Run by
- Forma Therapeutics, Inc.
See details and how to joinNCT05953584 - 4. fázisTaking peopleRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- Where
- Khoudh
- Életkor
- 6 hónap to 100 év
- People
- 130 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04657822 · EU 2024-510734-41-00